FCCC LOGO Faculty Publications
Pabla S , Conroy JM , Nesline MK , Glenn ST , Papanicolau-Sengos A , Burgher B , Hagen J , Giamo V , Andreas J , Lenzo FL , Yirong W , Dy GK , Yau E , Early A , Chen H , Bshara W , Madden KG , Shirai K , Dragnev K , Tafe LJ , Marin D , Zhu J , Clarke J , Labriola M , McCall S , Zhang T , Zibelman M , Ghatalia P , Araujo-Fernandez I , Singavi A , George B , MacKinnon AC , Thompson J , Singh R , Jacob R , Dressler L , Steciuk M , Binns O , Kasuganti D , Shah N , Ernstoff M , Odunsi K , Kurzrock R , Gardner M , Galluzzi L , Morrison C
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
J Immunother Cancer. 2019 Feb 1;7(1) :27
PMID: 30709424    PMCID: PMC6359802   
Back to previous list
Abstract
BACKGROUND: Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity to ICIs in non-small cell lung cancer (NSCLC) patients. METHODS: Tumor specimens from 120 NSCLC patients from 10 institutions were evaluated for PD-L1 expression by immunohistochemistry, and global proliferative profile by targeted RNA-seq. RESULTS: Cell proliferation, derived from the mean expression of 10 proliferation-associated genes (namely BUB1, CCNB2, CDK1, CDKN3, FOXM1, KIAA0101, MAD2L1, MELK, MKI67, and TOP2A), was identified as a marker of response to ICIs in NSCLC. Poorly, moderately, and highly proliferative tumors were somewhat equally represented in NSCLC, with tumors with the highest PD-L1 expression being more frequently moderately proliferative as compared to lesser levels of PD-L1 expression. Proliferation status had an impact on survival in patients with both PD-L1 positive and negative tumors. There was a significant survival advantage for moderately proliferative tumors compared to their combined highly/poorly counterparts (p = 0.021). Moderately proliferative PD-L1 positive tumors had a median survival of 14.6 months that was almost twice that of PD-L1 negative highly/poorly proliferative at 7.6 months (p = 0.028). Median survival in moderately proliferative PD-L1 negative tumors at 12.6 months was comparable to that of highly/poorly proliferative PD-L1 positive tumors at 11.5 months, but in both instances less than that of moderately proliferative PD-L1 positive tumors. Similar to survival, proliferation status has impact on disease control (DC) in patients with both PD-L1 positive and negative tumors. Patients with moderately versus those with poorly or highly proliferative tumors have a superior DC rate when combined with any classification schema used to score PD-L1 as a positive result (i.e., TPS >/= 50% or >/= 1%), and best displayed by a DC rate for moderately proliferative tumors of no less than 40% for any classification of PD-L1 as a negative result. While there is an over representation of moderately proliferative tumors as PD-L1 expression increases this does not account for the improved survival or higher disease control rates seen in PD-L1 negative tumors. CONCLUSIONS: Cell proliferation is potentially a new biomarker of response to ICIs in NSCLC and is applicable to PD-L1 negative tumors.
Notes
2051-1426 Pabla, Sarabjot Conroy, Jeffrey M Nesline, Mary K Glenn, Sean T Papanicolau-Sengos, Antonios Burgher, Blake Hagen, Jacob Giamo, Vincent Andreas, Jonathan Lenzo, Felicia L Yirong, Wang Dy, Grace K Yau, Edwin Early, Amy Chen, Hongbin Bshara, Wiam Madden, Katherine G Shirai, Keisuke Dragnev, Konstantin Tafe, Laura J Marin, Daniele Zhu, Jason Clarke, Jeff Labriola, Matthew McCall, Shannon Zhang, Tian Zibelman, Matthew Ghatalia, Pooja Araujo-Fernandez, Isabel Singavi, Arun George, Ben MacKinnon, Andrew Craig Thompson, Jonathan Singh, Rajbir Jacob, Robin Dressler, Lynn Steciuk, Mark Binns, Oliver Kasuganti, Deepa Shah, Neel Ernstoff, Marc Odunsi, Kunle Kurzrock, Razelle Gardner, Mark Galluzzi, Lorenzo Morrison, Carl ORCID: http://orcid.org/0000-0002-3441-8363 Journal Article England J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.